Scribe Therapeutics Inc (SCTX)

$27.11 +5.92 (27.94%)
Market Cap 364.37M
Revenue (ttm) 51.17M
Net Income (ttm) -21.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -42.62%
Debt to Equity Ratio 0.00
Volume 506,094
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 17.58M
Stochastic %K 28%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with eleva...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 626 8587
Address:
1150 Marina Village Pkwy, Alameda, United States
notreload_ai
notreload_ai Aug. 18 at 7:49 PM
Multiple firms initiate coverage on $SCTX with Buy ratings and targets up to $60 after its IPO, spotlighting CRISPR tech for cholesterol. https://notreload.xyz/xy/guggenheim-leerink-wells-fargo-goldman-initiate-coverage-on-sctx/
0 · Reply
handmedown1
handmedown1 Aug. 18 at 4:53 PM
$CRSP analyst are tripping themselves to upgrade $SCTX ...meanwhile crispy is just a pile of garbage
0 · Reply
Momabeat
Momabeat Aug. 18 at 3:57 PM
$SCTX hesitated on this one. Regrets. Good job bulls!!
0 · Reply
CDMO
CDMO Aug. 18 at 3:21 PM
$SCTX damn! Interesting one
0 · Reply
IPO_Candy
IPO_Candy Aug. 18 at 3:13 PM
$SCTX This is one new IPO we think investors should put on their list. It's a rare biotech that we own in some size. Too complicated to explain here but Leerink was the lead on this one, $LLY and $SNY both investors with substantial milestones around lead programs. Really interesting and important science going on here.
0 · Reply
soksobay
soksobay Aug. 18 at 2:48 PM
$SCTX Analyst Coverage and TargetsWells Fargo: Overweight rating with a $60 price target (183% potential upside).Guggenheim: Buy rating with a $50 price target (136% potential upside).Leerink Partners: Outperform rating with a $37 price target (75% potential upside)
0 · Reply
soksobay
soksobay Aug. 18 at 2:47 PM
$SCTX This gene-based therapeutics stock could nearly triple, analysts say. Differentiated Approach: The excitement centers on Scribe's lead asset, STX-1150, an epigenetic silencing therapy targeting the PCSK9 gene.No Permanent DNA Alteration: The treatment aims to lower LDL cholesterol without permanently cutting or changing a patient's underlying genetic code, minimizing off-target editing risks.Long-Term Durability: Analysts highlight the potential for years-long therapeutic durability compared to chronic or frequent standard dosing methods
0 · Reply
Wolfman5960
Wolfman5960 Aug. 17 at 4:56 PM
$SCTX The Ionis/Novartis Lp(a)HORIZON CVOT should be reading out soon: https://clinicaltrials.gov/study/NCT04023552 Important trial that can validate Lp(a) as a target to reduce cardiovascular risk. STX-1200 is Scribe's program targeting Lp(a) using their XE tech.
0 · Reply
Wolfman5960
Wolfman5960 Aug. 15 at 1:29 AM
$SCTX Started a position in Scribe today. Good scientific team, strong IP, backed by a16z, and partnerships with Eli Lilly/Prevail and Sanofi. I like the epigenetic silencing aspect of being able to silence a gene without having to edit or cut the DNA. The technology might have the potential to make siRNAs obsolete if safety holds up long term. The S1 filing also mentioned obesity and MASH targets as well so I'm guessing they might go after INHBE as a target. Sitting at a $335 million market cap currently and well funded with the recent IPO it'll be interesting to see what price targets analysts come up with when the post IPO quiet period expires. Years and years away from market, but overall an interesting company with a lot of potential. Hopefully they can execute properly.
1 · Reply
Greenthought
Greenthought Aug. 7 at 11:54 PM
$ONFO starter position for Monday PM—- $SCTX $SXTC, don’t forget $LBGJ this still have room to pop… Next week.
0 · Reply
Latest News on SCTX
Leerink starts Scribe Therapeutics at Outperform on X-editor platform

2026-08-18T17:10:10.000Z - 5 hours ago

Leerink starts Scribe Therapeutics at Outperform on X-editor platform

Scribe Therapeutics initiated with an Outperform at Leerink

2026-08-18T10:10:25.000Z - 12 hours ago

Scribe Therapeutics initiated with an Outperform at Leerink

Scribe Therapeutics initiated with a Buy at Guggenheim

2026-08-18T09:35:06.000Z - 12 hours ago

Scribe Therapeutics initiated with a Buy at Guggenheim

Scribe Therapeutics initiated with an Overweight at Wells Fargo

2026-08-18T09:05:07.000Z - 13 hours ago

Scribe Therapeutics initiated with an Overweight at Wells Fargo

Scribe Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

2026-08-18T08:15:11.000Z - 14 hours ago

Scribe Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

Jul 27, 2026, 4:05 PM EDT - 22 days ago

Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement

Opening Day: Scribe Therapeutics makes strong trading debut

2026-07-27T15:25:46.000Z - 22 days ago

Opening Day: Scribe Therapeutics makes strong trading debut

BCCQ BSP CCCT CGCF ECR FDMM FWAC

Scribe Therapeutics opens at $25, IPO priced at $15 per share

2026-07-24T16:00:48.000Z - 25 days ago

Scribe Therapeutics opens at $25, IPO priced at $15 per share

Scribe Therapeutics indicated to open at $25, IPO priced at $15 per share

2026-07-24T15:25:24.000Z - 25 days ago

Scribe Therapeutics indicated to open at $25, IPO priced at $15 per share

Scribe Therapeutics indicated to open at $29.20, IPO priced at $15 per share

2026-07-24T15:00:12.000Z - 25 days ago

Scribe Therapeutics indicated to open at $29.20, IPO priced at $15 per share

Scribe Therapeutics 8.58M share IPO priced at $15.00

2026-07-24T10:05:34.000Z - 25 days ago

Scribe Therapeutics 8.58M share IPO priced at $15.00

Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering

Jul 23, 2026, 9:08 PM EDT - 25 days ago

Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering

Scribe Therapeutics IPO Registration Document (S-1)

Jul 2, 2026, 4:46 PM EDT - 6 weeks ago

Scribe Therapeutics IPO Registration Document (S-1)

Cardiovascular diseases biotech Scribe Therapeutics files for a $75 million IPO

Jul 2, 2026, 1:30 PM EDT - 6 weeks ago

Cardiovascular diseases biotech Scribe Therapeutics files for a $75 million IPO

notreload_ai
notreload_ai Aug. 18 at 7:49 PM
Multiple firms initiate coverage on $SCTX with Buy ratings and targets up to $60 after its IPO, spotlighting CRISPR tech for cholesterol. https://notreload.xyz/xy/guggenheim-leerink-wells-fargo-goldman-initiate-coverage-on-sctx/
0 · Reply
handmedown1
handmedown1 Aug. 18 at 4:53 PM
$CRSP analyst are tripping themselves to upgrade $SCTX ...meanwhile crispy is just a pile of garbage
0 · Reply
Momabeat
Momabeat Aug. 18 at 3:57 PM
$SCTX hesitated on this one. Regrets. Good job bulls!!
0 · Reply
CDMO
CDMO Aug. 18 at 3:21 PM
$SCTX damn! Interesting one
0 · Reply
IPO_Candy
IPO_Candy Aug. 18 at 3:13 PM
$SCTX This is one new IPO we think investors should put on their list. It's a rare biotech that we own in some size. Too complicated to explain here but Leerink was the lead on this one, $LLY and $SNY both investors with substantial milestones around lead programs. Really interesting and important science going on here.
0 · Reply
soksobay
soksobay Aug. 18 at 2:48 PM
$SCTX Analyst Coverage and TargetsWells Fargo: Overweight rating with a $60 price target (183% potential upside).Guggenheim: Buy rating with a $50 price target (136% potential upside).Leerink Partners: Outperform rating with a $37 price target (75% potential upside)
0 · Reply
soksobay
soksobay Aug. 18 at 2:47 PM
$SCTX This gene-based therapeutics stock could nearly triple, analysts say. Differentiated Approach: The excitement centers on Scribe's lead asset, STX-1150, an epigenetic silencing therapy targeting the PCSK9 gene.No Permanent DNA Alteration: The treatment aims to lower LDL cholesterol without permanently cutting or changing a patient's underlying genetic code, minimizing off-target editing risks.Long-Term Durability: Analysts highlight the potential for years-long therapeutic durability compared to chronic or frequent standard dosing methods
0 · Reply
Wolfman5960
Wolfman5960 Aug. 17 at 4:56 PM
$SCTX The Ionis/Novartis Lp(a)HORIZON CVOT should be reading out soon: https://clinicaltrials.gov/study/NCT04023552 Important trial that can validate Lp(a) as a target to reduce cardiovascular risk. STX-1200 is Scribe's program targeting Lp(a) using their XE tech.
0 · Reply
Wolfman5960
Wolfman5960 Aug. 15 at 1:29 AM
$SCTX Started a position in Scribe today. Good scientific team, strong IP, backed by a16z, and partnerships with Eli Lilly/Prevail and Sanofi. I like the epigenetic silencing aspect of being able to silence a gene without having to edit or cut the DNA. The technology might have the potential to make siRNAs obsolete if safety holds up long term. The S1 filing also mentioned obesity and MASH targets as well so I'm guessing they might go after INHBE as a target. Sitting at a $335 million market cap currently and well funded with the recent IPO it'll be interesting to see what price targets analysts come up with when the post IPO quiet period expires. Years and years away from market, but overall an interesting company with a lot of potential. Hopefully they can execute properly.
1 · Reply
Greenthought
Greenthought Aug. 7 at 11:54 PM
$ONFO starter position for Monday PM—- $SCTX $SXTC, don’t forget $LBGJ this still have room to pop… Next week.
0 · Reply
topstockalerts
topstockalerts Aug. 4 at 7:28 PM
Top Gainers $STAK $LVWR $WLDS $NIPG $SCTX
0 · Reply
SocioCobb
SocioCobb Jul. 30 at 12:23 AM
$SCTX open market! 👀
0 · Reply
Zardiw
Zardiw Jul. 29 at 1:33 PM
$SOFI - #DDAmanda Chart. Bullish or bearish? Watching these too: $RAY.X $SCTX $TC Best Stock Screener + Dilution Tracker: https://DDAmanda.com
0 · Reply
Zardiw
Zardiw Jul. 29 at 12:10 PM
Another DDAmanda find: $AMIX +73% - Caught it before the crowd showed up. Previously flagged: $NDLS $LVWR $SCTX Which one are you watching next:: https://DDAmanda.com
0 · Reply
StockDeni
StockDeni Jul. 29 at 11:49 AM
$SCTX
0 · Reply
Josema66
Josema66 Jul. 29 at 11:37 AM
$SCTX A private placement of nearly 2.4 million shares held by a company director—worth $36 million—was announced; nobody puts up $36 million without having insider information.
0 · Reply
yus37
yus37 Jul. 28 at 9:34 AM
$SCTX
0 · Reply
theflynews
theflynews Jul. 27 at 3:27 PM
Opening Day: Scribe Therapeutics makes strong trading debut - $SCTX - https://thefly.com/SCTX
0 · Reply
IPOtweet
IPOtweet Jul. 27 at 1:00 PM
IPO Winners & Losers: Jersey Mike's, Bubble Baths, and Biotech Wins $JMKE $REF $SCTX $IPO #IPO https://zpr.io/RZDKTieFGQhX
0 · Reply
Zardiw
Zardiw Jul. 27 at 12:38 PM
$DFNS showing up on DDAmanda. Also found: $LVWR $OMH $SCTX Best Stock Screener - Dilution Tracker: https://DDAmanda.com
1 · Reply
Zardiw
Zardiw Jul. 27 at 10:14 AM
$LGHL is running - where does it stop? DDAmanda Chart Also found early: $OMH $NIPG $SCTX Anyone watching this one? https://DDAmanda.com
0 · Reply
topstockalerts
topstockalerts Jul. 26 at 9:57 PM
Top Gainers $STAK $LVWR $WLDS $NIPG $SCTX
0 · Reply